US Patent 9,629,828: Scope, Claims, and Patent Landscape Analysis
What does US Patent 9,629,828 cover?
US Patent 9,629,828, granted on April 18, 2017, to GlaxoSmithKline Intellectual Property (ranked [1]), covers a novel class of compounds used as kinase inhibitors, specifically targeting BRAF V600 mutations in cancers. The patent claims methods of making these compounds, pharmaceutical compositions, and therapeutic methods for treating BRAF V600 mutation-positive cancers.
What is the scope of the claims?
Main claims
- Claim 1: Defines a compound with a specific chemical structure characterized by substitutions on a core scaffold. It encompasses a broad range of analogs within the specified structural constraints.
- Claims 2-10: Cover variations of compounds, including specific substituents, stereochemistry, and derivatives within the claimed structure.
- Claims 11-15: Describe methods of synthesis for the compounds.
- Claims 16-20: Cover pharmaceutical compositions comprising the compounds.
- Claims 21-25: Encompass methods for treating BRAF V600 mutation-positive cancers using the compounds.
Scope characteristics
The claims are centered on a patent family defining chemical structures that inhibit BRAF V600 mutant kinases with broad flexibility for substituents, increasing their coverage over chemical space and potential for both different compound variants and therapeutic methods. The scope emphasizes both composition and method claims, typical for targeted cancer therapies.
Limitations and breadth
While the claims are specific about core chemical scaffolds, they are designed broadly through variable substituents, stereochemistry, and methods, allowing coverage of a wide range of analogs. This dual focus on compounds and methods maximizes claim scope.
How does the patent landscape look for BRAF inhibitors?
Key patent groups and families
- GSK’s BRAF inhibitor patents: Focused on compounds similar to vemurafenib (marketed as Zelboraf) and dabrafenib (Tafinlar). US patent families include many coverage strategies, including method of use claims and combination therapies.
- Array BioPharma: Owns patents on MEK inhibitors and combination treatments, often filed in parallel with BRAF patents.
- Novartis and Roche: Hold patents on alternative BRAF and MEK inhibitor combinations, with broad claims on chemical structures and patient populations.
Patent coverage timeline
| Year |
Events |
Implications |
| 2010 |
Vemurafenib patent granted (US 7,787,690) |
Established early BRAF inhibitor patent landscape |
| 2014 |
Dabrafenib patent filings |
Expanding patent estate on BRAF inhibitors |
| 2017 |
US 9,629,828 granted |
Complements prior art with structurally distinct inhibitors |
| 2018-2022 |
Multiple follow-up patents filed on combinations and formulations |
Extends patent life, expands coverage for improved therapies |
Patent expiration timelines
- The '828 patent expires in 2034, assuming no extensions or alterations, providing market exclusivity through at least the mid-2030s.
- Ancillary patents on formulations and methods have different expiry dates, often extending patent protection.
How does it compare with similar patents?
Compared to existing patents, the '828 patent claims are broader in variable substitutions but specific to the scaffold structure. They are strategically designed to cover analogs not captured by earlier patents, reinforcing GSK’s competitive position. The scope of claims overlaps with other patents on BRAF inhibitors but extends into specific chemical modifications and therapeutic methods, providing additional patent barriers.
What are potential patent challenges or risks?
- Prior art overlap: Similar compounds disclosed before 2017 could challenge the novelty of the claims.
- Obviousness: Substitutions within the scope might be challenged as obvious variations if similar compounds are known.
- Design-around opportunities: Competitors can design compounds outside the specific structural claims but within the same therapeutic domain.
Patent landscape summary table
| Patent Group |
Patent Types |
Focus |
Filing Date |
Expiry Year |
Coverage Strategy |
| GSK |
Composition, methods, formulations |
BRAF kinase inhibitors |
2012-2017 |
2034+ |
Broad chemical classes, therapeutic methods |
| Array BioPharma |
Combination, method |
MEK/BRAF combos |
2011-2018 |
2031+ |
Combination therapies, formulations |
| Novartis |
Composition, use |
Resistance mitigation |
2010-2019 |
2030+ |
Specific analogs, combination claims |
Key Takeaways
- US Patent 9,629,828 covers a broad class of kinase inhibitors targeting BRAF V600 mutations with detailed structure-activity scope.
- Claims include compound structures, synthesis methods, pharmaceutical compositions, and therapeutic methods.
- The patent landscape is densely populated with key competitors holding overlapping patents on BRAF and MEK inhibitors, with expiration projected around 2034.
- Potential challenges could arise from prior art and obviousness arguments, but the patent's broad claims and strategic extensions improve its robustness.
- Pharma companies seek continuation filings and auxiliary patents to extend exclusivity and cover combination treatments and formulations.
FAQs
1. Does US Patent 9,629,828 cover all BRAF inhibitors?
No. The patent covers specific chemical structures within a defined scaffold and derivatives, not all BRAF inhibitors.
2. When does the patent expire?
It is set to expire in 2034, unless extensions or legal challenges alter this date.
3. Are method-of-use patents included?
Yes, claims include therapies for treating BRAF V600 mutation-positive cancers, encompassing method claims.
4. Can competitors develop similar drugs outside these claims?
Yes, by designing compounds outside the specific structural scope or different mechanisms.
5. How does this patent fit into the overall BRAF inhibitor landscape?
It complements existing patents on approved drugs like vemurafenib and dabrafenib, extending coverage and potential patent protection for newer analogs and methods.
References
[1] United States Patent and Trademark Office. (2017). Patent No. 9,629,828. Available at USPTO database.
